HUP0401042A2 - Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények - Google Patents

Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP0401042A2
HUP0401042A2 HU0401042A HUP0401042A HUP0401042A2 HU P0401042 A2 HUP0401042 A2 HU P0401042A2 HU 0401042 A HU0401042 A HU 0401042A HU P0401042 A HUP0401042 A HU P0401042A HU P0401042 A2 HUP0401042 A2 HU P0401042A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
primary insomnia
compositions suitable
treating primary
melatonin
Prior art date
Application number
HU0401042A
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401042(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of HUP0401042A2 publication Critical patent/HUP0401042A2/hu
Publication of HUP0401042A3 publication Critical patent/HUP0401042A3/hu
Publication of HU230786B1 publication Critical patent/HU230786B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

A találmány primer álmatlanság kezelésére és regeneráló alvásminőségjavítására alkalmas gyógyszerkészítményre vonatkozik, amely legalábbegy vegyület, mégpedig melatonin, egyéb melatonerg anyag, melatoninagonista és melatonin antagonista 0,0025 mg és 50 mg közötti hatásosmennyiségét tartalmazza adott esetben egy vagy több egyéb terápiáshatású szerrel és hordozó- és/vagy segédanyaggal összekeverve. Ó
HU0401042A 2001-08-14 2002-08-12 Pharmaceutical compositions suitable for treating primary insomnia HU230786B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
PCT/IL2002/000662 WO2003015690A2 (en) 2001-08-14 2002-08-12 Method for treating primary insomnia

Publications (3)

Publication Number Publication Date
HUP0401042A2 true HUP0401042A2 (hu) 2004-08-30
HUP0401042A3 HUP0401042A3 (en) 2009-07-28
HU230786B1 HU230786B1 (en) 2018-05-02

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401042A HU230786B1 (en) 2001-08-14 2002-08-12 Pharmaceutical compositions suitable for treating primary insomnia

Country Status (35)

Country Link
US (1) US8962024B2 (hu)
EP (2) EP1441702B1 (hu)
JP (1) JP2005501095A (hu)
KR (1) KR20040032917A (hu)
CN (1) CN100453078C (hu)
AR (1) AR034975A1 (hu)
AU (1) AU2002326114C1 (hu)
BR (1) BR0211855A (hu)
CA (1) CA2454699C (hu)
CL (1) CL2002001701A1 (hu)
CR (1) CR7271A (hu)
CY (2) CY1118924T1 (hu)
DK (2) DK3103443T3 (hu)
EA (1) EA200400302A1 (hu)
ES (2) ES2626591T3 (hu)
GT (1) GT200200164A (hu)
HK (1) HK1066161A1 (hu)
HU (1) HU230786B1 (hu)
IL (1) IL144900A (hu)
IS (1) IS3004B (hu)
JO (1) JO3446B1 (hu)
LT (1) LT1441702T (hu)
MX (1) MXPA04001372A (hu)
NO (1) NO334788B1 (hu)
NZ (1) NZ531318A (hu)
PA (1) PA8552301A1 (hu)
PE (1) PE20030331A1 (hu)
PL (1) PL367872A1 (hu)
PT (2) PT1441702T (hu)
RU (1) RU2560840C2 (hu)
SI (1) SI1441702T1 (hu)
UA (1) UA87262C2 (hu)
UY (1) UY27401A1 (hu)
WO (1) WO2003015690A2 (hu)
ZA (1) ZA200402005B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
HUE051362T2 (hu) 2016-10-31 2021-03-01 Neurim Pharma 1991 Melatonin minitabletták és eljárás azok elõállítására
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378110B (hu) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378109B (hu) 1972-05-19 1975-08-18 Bofors Ab
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
EP0518468B1 (en) 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0565296T3 (da) * 1992-04-07 1996-12-09 Neurim Pharma 1991 Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
DE69323768T2 (de) 1992-12-17 1999-07-01 Pfizer Pyrrolopyrimidine als crf antagonisten
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
WO1994013661A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Substituted pyrazoles as crf antagonists
WO1994013643A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having crf antagonist activity
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
CA2260269A1 (en) * 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
DE60034373T2 (de) * 2000-01-05 2007-12-20 Neurim Pharmaceuticals (1991) Ltd. Methode und zusammensetzung zur behandlung von resistenz gegen antihypertensiva und verwandten zuständen
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
WO2013049167A1 (en) 2011-09-27 2013-04-04 IBIS Medical, Inc. Intragastric implant devices

Also Published As

Publication number Publication date
JO3446B1 (ar) 2020-07-05
ES2626591T3 (es) 2017-07-25
EA200400302A1 (ru) 2004-10-28
LT1441702T (lt) 2017-06-12
AR034975A1 (es) 2004-03-24
WO2003015690A3 (en) 2003-09-25
WO2003015690A2 (en) 2003-02-27
GT200200164A (es) 2003-09-26
KR20040032917A (ko) 2004-04-17
PL367872A1 (en) 2005-03-07
ZA200402005B (en) 2005-07-27
IS7136A (is) 2004-01-30
SI1441702T1 (sl) 2017-08-31
CY1124763T1 (el) 2022-07-22
CY1118924T1 (el) 2018-01-10
MXPA04001372A (es) 2005-06-06
AU2002326114A1 (en) 2003-03-03
DK1441702T3 (en) 2017-06-06
ES2882584T3 (es) 2021-12-02
AU2002326114B2 (en) 2007-03-08
CN1541092A (zh) 2004-10-27
HU230786B1 (en) 2018-05-02
EP1441702B1 (en) 2017-05-10
EP3103443B1 (en) 2021-06-30
NO334788B2 (no) 2014-05-26
PT1441702T (pt) 2017-06-02
US20040248966A1 (en) 2004-12-09
UY27401A1 (es) 2003-02-28
NZ531318A (en) 2005-08-26
CN100453078C (zh) 2009-01-21
CR7271A (es) 2004-05-17
NO334788B1 (no) 2014-05-26
JP2005501095A (ja) 2005-01-13
IS3004B (is) 2018-09-15
UA87262C2 (uk) 2009-07-10
WO2003015690B1 (en) 2004-03-11
BR0211855A (pt) 2004-09-21
EP1441702A4 (en) 2007-09-26
CL2002001701A1 (es) 2010-06-25
CA2454699C (en) 2012-03-27
IL144900A0 (en) 2002-06-30
PT3103443T (pt) 2021-08-12
HUP0401042A3 (en) 2009-07-28
HK1066161A1 (en) 2005-03-18
EP3103443A1 (en) 2016-12-14
CA2454699A1 (en) 2003-02-27
EP1441702A2 (en) 2004-08-04
IL144900A (en) 2013-12-31
PA8552301A1 (es) 2003-06-30
US8962024B2 (en) 2015-02-24
DK3103443T3 (da) 2021-08-30
NO20040087L (no) 2004-02-19
RU2560840C2 (ru) 2015-08-20
PE20030331A1 (es) 2003-06-27
RU2011131532A (ru) 2013-03-27
AU2002326114C1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
HK1095139A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
IL175714A0 (en) Quinazolinone compounds as anticancer agents
HK1071890A1 (en) Spiroazacyclic compounds as monoamine receptor modulators
RS20090083A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta -mimetics
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BR0008059A (pt) Composições de valdecoxib
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
SE9903997D0 (sv) New compounds
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
HUP0300848A2 (hu) Kamptotecint és egy pirimidinszármazékot tartalmazó készítmény rák kezelésére
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
TW200501948A (en) Composition for improving cognition and memory
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
HK1047547A1 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
IL175357A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
EP1908462A3 (en) Dichloroacetate in combination with cardioprotective or hemodynamic drugs